Brands
Badshah’s Badboy Pizza slips into India’s QSR scene with a bold, desi twist
MUMBAI: Critically acclaimed rapper, singer-songwriter and serial entrepreneur Badshah has fired up the ovens and stormed into India’s booming quick service restaurant (QSR) sector with Badboy Pizza—a mass-premium pizza chain that promises bold flavours, slick branding, and a desi-meets-global attitude.
The artist, whose real name is Aditya Prateek Singh Sisodia, has teamed up with Ghost Kitchens India, one of the country’s largest cloud kitchen players led by serial founder Karan Tanna, to build what the duo claim will be “the most exciting QSR launch of the decade.”
Ahead of the opening, the internet was set ablaze with a cheeky viral campaign featuring Badshah being slapped—by a pizza. The stunt, designed to juice the brand’s tagline ‘pizza that slaps,’ racked up over eight million views across platforms and turbocharged buzz around the brand’s launch.
Badboy Pizza is now live with a flagship boutique outlet in Andheri, Mumbai, and is eyeing a footprint of 50 locations across India’s top five metros in the next three years. Built as a hybrid format of dine-in and delivery kitchens, the brand is chasing an ambitious Rs150 crore annual recurring revenue (ARR) target. The average bill: Rs 400 per person.
At the heart of the venture is a 50-item cosmopolitan menu that fuses global favourites with desi swagger—from Truffle Cacio-e-Pepe and Korean Spice to Tandoori Tikka and Chicken Keemalal. There’s even a cinematic special called the Pushpa Pizza, spicy enough to match its namesake’s fire.
Says Badshah: “Badboy Pizza is an extension of my personality — rooted, bold and real and this launch is special since I’ve always dreamt of having my own pizza chain! Drawing upon diverse culinary experiences from my travels over the years, my vision was to forge a brand that embodies international quality while resonating deeply with homegrown appeal. Partnering with Karan Tanna and Ghost Kitchens ensures we’re building not just a brand, but a truly world class and accessible culinary experience.”
The crust, however, is the true hero. Made with Italian flour and cold fermented for 48 hours, it promises that elusive combo of crispy outside and fluffy inside—a far cry from the usual QSR fare.
And the brand doesn’t stop at pizza. The menu includes garlic bread with butter chicken, spaghetti in bread bowls, flamboyant desserts like Fried Oreos with sea salt dark chocolate, and madcap sundaes in flavours such as Banaras Paan and Guava Masala.
The brand identity? Loud, rebellious and proudly Indie-an. Badboy Pizza’s packaging mimics smuggled contraband—zesty lime and purple boxes emblazoned with bold typography and the playful wink of Jugnu, the mischievous mascot who glows when things get bold. The boxes double up as collectible street-art souvenirs—because why should a pizza box be boring?
For Ghost Kitchens, the tie-up is a strategic masterstroke. Already home to brands like Starboy Pizza and Speak Burgers by Vicky Ratnani, the cloud-first company processes over 1.2 lakh orders monthly and is scaling fast after a $5 million Series A raise in 2024.
Tanna said, “Badboy Pizza is poised to be the most exciting QSR launch of the decade. The brand reimagines what scalable QSRs of the future will look like. Badshah’s ability to shape trends and influence youth culture gives this brand an unmatched edge. Together, we’re building the future of QSR experiences in India.”
India’s QSR market is surging—from $85.19 billion in 2025 to a projected $139.75 billion by 2030, growing at a CAGR of 10.41 per cent, according to a press release issued by the company. The pizza segment alone is forecast to more than double to $11.8 billion by 2033.
With the hype machine firing on all cylinders, a menu that dares to be different, and cultural cues baked into every bite, Badboy Pizza isn’t just selling food. It’s building a movement.
And yes—this pizza really slaps.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
